Evidence map›Paper›PMID 41021024›Full record

GuidelineWiener klinische Wochenschrift2025

[Recommendations for the Diagnosis and Treatment of Chronic Kidney Disease (CKD) by the Austrian Society of Nephrology].

Sara H Ksiazek, Martin Windpessl, Emanuel Zitt, Michael Rudnicki, Kathrin Eller, Christoph Schwarz, Marlies Antlanger, Sabine Schmaldienst, Daniel Cejka, Rainer Oberbauer and 2 more

Abstract readPractice GuidelineEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Wiener klinische Wochenschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sara H Ksiazek6. Medizinische Abteilung mit Nephrologie & Dialyse, Klinik Ottakring, Wien, Österreich. sara.ksiazek@hotmail.com.
Martin WindpesslAbteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, Wels, Österreich.
Emanuel ZittAbteilung für Innere Medizin III (Nephrologie, Dialyse und Hypertensiologie), Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, Österreich.
Michael RudnickiDepartment Innere Medizin IV (Nephrologie und Hypertensiologie), Medizinische Universität Innsbruck, Innsbruck, Österreich.
Kathrin EllerKlinische Abteilung für Nephrologie, Abteilung für Innere Medizin, Medizinische Universität Graz, Graz, Österreich.
Christoph SchwarzInnere Medizin 1, Pyhrn-Eisenwurzenklinikum, Sierningerstr. 170, 4400, Steyr, Österreich.
Marlies AntlangerKepler Universitätsklinikum Linz, Universitätsklinik für Innere Medizin 2, Linz, Österreich.
Sabine Schmaldienst1. Medizinische Abteilung mit Nephrologie, Intensivmedizin, Psychosomatik und Diabetologie, Klinik Favoriten, Wien, Österreich.
Daniel CejkaAbteilung für Innere Medizin III, Nieren- und Hochdruckerkrankungen, Transplantationsmedizin, Rheumatologie, Akutgeriatrie, Ordensklinikum Linz - Krankenhaus der Elisabethinen, Fadingerstr. 1, 4020, Linz, Österreich.
Rainer OberbauerUniversitätsklinik für Innere Medizin III, Abt. für Nephrologie und Dialyse, Medizinische Universität Wien, Wien, Österreich.
Alexander R RosenkranzKlinische Abteilung für Nephrologie, Abteilung für Innere Medizin, Medizinische Universität Graz, Graz, Österreich.
Marcus D Säemann6. Medizinische Abteilung mit Nephrologie & Dialyse, Klinik Ottakring, Wien, Österreich.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) affects over 800 million people worldwide, yet only about 6-10% of those affected are aware of their condition. Limited public awareness and insufficient structural measures in the healthcare system lead to the fact that CKD is frequently not diagnosed or diagnosed after a delay and therefore insufficiently treated. Current projections estimate that CKD could become the fifth leading cause of death worldwide by 2040, if timely and effective measures to increase awareness and early detection are not implemented. This article presents practice-oriented guidelines for the screening, diagnostics and treatment of CKD in Austria. It outlines for which risk groups screening is recommended and describes how physicians can diagnose and treat CKD across all medical specialties. A key aspect of these guidelines is the presentation of pharmacological treatment options that slow disease progression, with specific indications and practical clinical recommendations for their use. Furthermore, the recommendations address nationally defined referral criteria to nephrology specialists in Austria and discusses possible CKD-related complications along with appropriate treatment strategies.

Indexed as

Mass ScreeningNephrologyRenal Insufficiency, ChronicAustriaHumansAlbuminuriaChronic kidney diseaseCystatin CGlomerular filtration rateNephroprotection

Identifiers

PMID41021024
PMCPMC12479600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.